Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abcellera Biologics Inc, Us HealthfiledCriticalAbcellera Biologics Inc
Publication of AR120759A1publicationCriticalpatent/AR120759A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
Anticuerpos que se unen a la proteína espicular de SARS-CoV, la proteína espicular de SARSCoV-2, y métodos para usarlos para tratar o prevenir afecciones asociadas al SARS o COVID-19 y para detectar SARS-CoV o SARS-CoV-2. Reivindicación 20: El anticuerpo o fragmento de unión al antígeno de este de cualquiera de las reivindicaciones 1 - 17, que tiene reactividad cruzada con la proteína espicular de SARS-CoV y la proteína espicular de SARS-CoV-2.Antibodies that bind to the spike protein of SARS-CoV, the spike protein of SARSCoV-2, and methods of using them to treat or prevent conditions associated with SARS or COVID-19 and to detect SARS-CoV or SARS-CoV-2. Claim 20: The antibody or antigen-binding fragment thereof of any of claims 1-17, which is cross-reactive with the spike protein of SARS-CoV and the spike protein of SARS-CoV-2.
ARP200103485A2020-03-092020-12-14
ANTI-CORONAVIRUS ANTIBODIES AND METHODS OF USE
AR120759A1
(en)
Monoclonal antibodies that specifically bind to the plasminogen activator inhibitor type 1 (pai-1); and use to prepare a useful medicine to restore plasmin generation or treat a condition caused by increased levels of pai-1 or increased sensitivity to pai-1.